Lesson 10 of Space Radiation Foundations: comparing doses across the ISS, lunar missions, and Mars transit, and what acute vs. career radiation risk means in plain terms
Radiation and the Human Body in Space
What you’ll learn
Compare radiation doses across ISS, lunar, and Mars-transit missions, and explain the difference between acute and career radiation risk in plain terms.
Lesson 10 of Space Radiation Foundations: comparing doses across the ISS, lunar missions, and Mars transit, and what acute vs. career radiation risk means in plain terms
A six-month stay on the ISS delivers a radiation dose thousands of times larger than a single chest X-ray — and a round-trip to Mars would deliver several times more than that six-month ISS stay. Lesson 9 showed what radiation does to hardware when it goes unaccounted for; this final lesson in Space Radiation Foundations turns to the other thing radiation dose is measured against — a human body — and puts real mission doses side by side on one scale, in sievert (Sv) and rem, the equivalent-dose units this course has been building toward since Lesson 7.
!Diagram: a ladder comparing radiation doses on a common millisievert scale — a chest X-ray at 0.02 millisieverts, a six-month ISS stay at 80 to 160 millisieverts, and a representative ~180-day one-way Mars transit at roughly 300 millisieverts, derived from a measured GCR rate of 1.8 millisieverts per day.
The Direct Answer
A six-month ISS mission delivers roughly 77–86 mSv of effective dose under NASA’s current design standard; a real, measured Artemis I lunar mission delivered about 27–35 mSv over roughly 25.5 days; and the measured Mars-transit dose rate is about 1.75 mSv per day, which adds up fast over a months-long cruise. Those numbers only mean something next to two reference points: a single chest X-ray (0.02 mSv) and the roughly 2.4 mSv an average person on Earth absorbs from natural background radiation in an entire year. NASA manages the risk from all of this with two separate limits — a per-event acute limit meant to prevent radiation sickness, and a lifetime career limit meant to cap cancer risk — and the two are not measuring the same thing.
The Concept
ISS crew dose rate
The current, binding NASA human-spaceflight design standard — NASA-STD-3001 Technical Brief OCHMO-TB-020, Rev G (NASA Office of the Chief Health & Medical Officer, revised 2025-06-06) — runs a sample calculation for a 180-day ISS mission and lands on a universal effective dose of 86 mSv (age 38, solar minimum) to 77 mSv (age 44, solar maximum). That same technical brief also sets binding GCR dose-rate design limits for spacecraft systems: below 1.3 mSv/day in free space, and below 0.9 mSv/day for systems on a planetary surface — ceiling values a mission is designed against, not the dose an ISS crew member actually accumulates day to day. An earlier NASA Marshall Space Flight Center educator guide, [“Space Faring: The Radiation Challenge”](https://www.nasa.gov/wp-content/uploads/2017/04/radiationchallenge.pdf) (2008) — the same figure the diagram accompanying this lesson is built from — put the same six-month window at a wider 80–160 mSv (80 mSv at solar maximum, 160 mSv at solar minimum, since GCR flux is actually higher when the Sun’s magnetic shielding is weaker). The two figures describe the same mission length but come from different NASA dose-model vintages 17 years apart; the current OCHMO-TB-020 range is the one to treat as authoritative.
Lunar mission dose
The best real data on lunar radiation dose comes from Artemis I, not a model. George, Gaza, Matthiä, et al. (2024), *Nature*, report a measured total mission dose equivalent of 26.7–35.4 mSv across different sensor locations inside the Orion capsule during its roughly 25.5-day uncrewed cislunar mission — with an interplanetary GCR cruise rate of 0.96–1.24 mSv/day, and Van Allen belt passes alone contributing 1.80–3.94 mSv (a single 90° spacecraft reorientation during belt transit cut that dose rate by roughly half). NASA’s own public restatement of these findings notes the measured Artemis I dose sits well below the 600 mSv NASA career limit (see below). It’s important not to treat this figure as interchangeable with a future crewed lunar-surface stay: Artemis I was a short, uncrewed, cislunar mission, not an extended stay on the lunar surface. OCHMO-TB-020’s own sample calculation models a notional 180-day lunar-surface mission at 167 mSv — a much longer, modeled scenario, not a measured one, and not directly comparable to Artemis I’s ~27–35 mSv without accounting for that duration and mission-profile difference.
Mars-transit dose
The Mars-transit figure in this lesson comes from an actual instrument that flew the route: the Radiation Assessment Detector (RAD) aboard the Mars Science Laboratory, which measured radiation continuously during Curiosity’s 253-day cruise to Mars. Guo, Zeitlin, Wimmer-Schweingruber, et al. (2015), *Astronomy & Astrophysics*, an open, peer-reviewed paper that independently restates and refines the original RAD measurement (Zeitlin et al. 2013, Science), puts the average GCR dose-equivalent rate during that cruise at 1.75 ± 0.30 mSv/day, for a total cruise dose equivalent of about 466 mSv over the full 253 days — including roughly 24.7 mSv (about 5%) from five separate solar particle events along the way. For shorter or longer transit windows, the same paper estimates 195 ± 98 mSv for a 180-day one-way transit under high solar modulation, and 360 ± 180 mSv for a 360-day round trip, both GCR-only estimates.
Acute vs. career risk
NASA manages astronaut radiation exposure with two limits that answer two different questions, per OCHMO-TB-020. The career limit is cumulative: an astronaut’s total career effective dose must stay under 600 mSv, a single number applied uniformly regardless of age or sex, set so that the added lifetime risk of radiation-attributable cancer death (on top of an unexposed baseline) stays at or below 3% on average. NASA’s own risk chart illustrates what that means in plain terms: a career-limit-compliant astronaut’s lifetime cancer-mortality risk rises from roughly 15% (unexposed baseline) to roughly 18% at the current 600 mSv standard. The acute limit is different in kind, not just in size: exposure from a single solar particle event is capped at 250 mSv effective dose per event, a limit set specifically to prevent short-term acute radiation syndrome — nausea, vomiting, fatigue, and blood-forming-organ depletion — rather than to manage long-term cancer risk. In plain terms: the career limit tracks what accumulates over a lifetime of missions; the acute limit tracks whether any single event, on its own, is severe enough to make someone sick right now.
Worked Example: ISS vs. Chest X-Ray vs. Annual Background
Comparison | Dose | Source |
|---|---|---|
ISS crew, 180-day mission | 77–86 mSv (age- and solar-cycle-dependent) | NASA OCHMO-TB-020, Rev G (2025) |
Chest X-ray, single view (posteroanterior) | 0.02 mSv | U.S. FDA (2010) |
Annual terrestrial background, worldwide average | 2.4 mSv/year | UNSCEAR 2008 Report, Vol. I, Annex B |
Lined up on the same scale: the low end of a 180-day ISS mission (77 mSv) is roughly 3,850 times a single chest X-ray, and roughly 32 times an entire year of ordinary background radiation on Earth’s surface — accumulated in about six months rather than one year.
Takeaway
Dose scales enormously with where and how long a human spends time in space — from a fraction of a background year for a chest X-ray, to tens of millisieverts for a real lunar mission, to hundreds of millisieverts for a Mars-transit cruise — and NASA manages that spread with two distinct limits: a per-event acute limit that guards against radiation sickness right now, and a cumulative career limit that guards against added lifetime cancer risk.
Key Facts
A 180-day ISS mission delivers 77–86 mSv of effective dose under NASA’s current (2025) design standard, versus an earlier 2008 estimate of 80–160 mSv for the same duration (NASA OCHMO-TB-020, Rev G, 2025; NASA MSFC, 2008).
Artemis I, a real measured cislunar mission (~25.5 days, uncrewed), delivered 26.7–35.4 mSv total, with an interplanetary GCR cruise rate of 0.96–1.24 mSv/day (George et al. 2024, Nature).
The measured Mars-transit GCR dose rate is 1.75 ± 0.30 mSv/day, for a total of about 466 mSv over Curiosity’s 253-day RAD-instrumented cruise (Guo et al. 2015, Astronomy & Astrophysics, refining Zeitlin et al. 2013, Science).
A single chest X-ray delivers 0.02 mSv; a worldwide average person absorbs about 2.4 mSv/year from natural background radiation (U.S. FDA, 2010; UNSCEAR 2008 Report).
NASA’s astronaut career dose limit is 600 mSv (capping added lifetime cancer-mortality risk at 3% mean), and its acute per-event limit is 250 mSv (capping risk of short-term radiation sickness) — two separate ceilings for two separate risks (NASA OCHMO-TB-020, Rev G, 2025).
FAQ
Why is a six-month ISS stay so much higher than a chest X-ray?
Because they’re not the same kind of exposure. A chest X-ray is a single, brief, deliberately minimized medical dose (0.02 mSv). An ISS crew member spends six months continuously exposed to trapped particles and galactic cosmic rays in low Earth orbit, accumulating 77–86 mSv over that period — thousands of times more, simply because the exposure is constant rather than momentary.
Is the Mars-transit dose rate higher than what ISS crews experience?
Per day, yes. The measured Mars-transit GCR rate is about 1.75 mSv/day, versus an ISS 180-day mission averaging out to well under 1 mSv/day. The difference comes down to shielding and location: the ISS sits inside Earth’s magnetosphere, which blocks a large share of galactic cosmic rays, while a Mars-transit spacecraft is in deep space with none of that protection.
Was the Artemis I dose the same as what a future crewed lunar mission would receive?
No, and this is a common mix-up. Artemis I was an uncrewed, roughly 25.5-day cislunar mission, and its measured 26.7–35.4 mSv reflects that short duration. NASA’s own sample calculation for a notional 180-day lunar-surface stay comes out to 167 mSv — a much longer, modeled scenario, not a measured one. The two numbers aren’t interchangeable without accounting for that duration difference.
Do the ISS or Mars-transit doses exceed NASA’s acute per-event limit?
Not on their own. NASA’s 250 mSv acute limit applies to a single solar particle event, not to routine cumulative dose from an ISS mission or Mars-transit cruise. Both the ISS and Mars-transit figures in this lesson are cumulative exposure over months, tracked against the separate 600 mSv career limit — a large solar particle event during either mission is the scenario the acute limit is actually designed to catch.
What’s the practical difference between the acute and career limits?
The acute limit (250 mSv per event) exists to prevent short-term radiation sickness — nausea, vomiting, fatigue — from a single intense event like a solar particle event. The career limit (600 mSv total) exists to keep an astronaut’s added lifetime cancer-mortality risk at or below 3%, accumulated across an entire career of missions. A single event can threaten the acute limit without coming close to the career limit, and routine cumulative exposure across missions can approach the career limit without ever threatening the acute one.
What’s Next
This is the final lesson in Space Radiation Foundations. For every conversion factor and representative dose value covered across this course — rad, gray, sievert, rem, flux, fluence, and LET — gathered in one place, see the Radiation Units Quick-Reference Table.
